Thermogenesis Holdings (THMO) rockets in reaction to FDA approval
Thermogenesis Holdings (THMO) currently trades at $7.26 and has grown by 58.13% today. THMO went up $2.67 from the previous closing price of $4.59. The high forecast for Thermogenesis Holdings is $9.00 and the low is $4.00. The company’s market cap is $33.39 million with a 52 week high of $8.78 and a 52 week low of $1.63. THMO has changed in price by 4.31 per share in the last 12 months. Shares of the company jumped in reaction to its announcement that the FDA has agreed that its COVID-19 antibody blood test has been properly validated and can now be distributed.
Thermogenesis Holdings has a weak EPS of -3.43. This means the company lost $-3.43 per share after paying dividends, this can indicate that the stock is a risky investment. EPS is calculated as a company’s profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company’s profitability. It is common for a company to report EPS that is adjusted for extraordinary items and potential share dilution. Based on this information, investorsQ rates this stock 5 out of 10. We give it this rating based on current information written in this article.
About Thermogenesis Holdings:
Thermogenesis Holdings is a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced financial and operating results for the year ended December 31, 2019 and provided a corporate strategic update.